Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Lattice Biologics Ltd. Announces Move To Belgrade, Montana June 26, 2017 Top GlaxoSmithKline Investor Cashes Out, Citing a Weak Pipeline and Lack of Strategic Options May 11, 2017 Alere Coughs Up $13 Million to Settle Accounting Fraud Charges With the September 28, 2017
Top GlaxoSmithKline Investor Cashes Out, Citing a Weak Pipeline and Lack of Strategic Options May 11, 2017